33 results on '"Shulenin, Sergey"'
Search Results
2. Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies.
- Author
-
Wirchnianski, Ariel S., Nyakatura, Elisabeth K., Herbert, Andrew S., Kuehne, Ana I., Abbasi, Shawn A., Florez, Catalina, Storm, Nadia, McKay, Lindsay G. A., Dailey, Leandrew, Kuang, Erin, Abelson, Dafna M., Wec, Anna Z., Chakraborti, Srinjoy, Holtsberg, Frederick W., Shulenin, Sergey, Bornholdt, Zachary A., Aman, M. Javad, Honko, Anna N., Griffiths, Anthony, and Dye, John M.
- Subjects
BISPECIFIC antibodies ,MARBURG virus ,EBOLA virus ,HEMORRHAGIC fever ,FILOVIRIDAE ,PROTEIN engineering - Abstract
Monoclonal antibodies (mAbs) are an important class of antiviral therapeutics. MAbs are highly selective, well tolerated, and have long in vivo half-life as well as the capacity to induce immune-mediated virus clearance. Their activities can be further enhanced by integration of their variable fragments (Fvs) into bispecific antibodies (bsAbs), affording simultaneous targeting of multiple epitopes to improve potency and breadth and/or to mitigate against viral escape by a single mutation. Here, we explore a bsAb strategy for generation of pan-ebolavirus and pan-filovirus immunotherapeutics. Filoviruses, including Ebola virus (EBOV), Sudan virus (SUDV), and Marburg virus (MARV), cause severe hemorrhagic fever. Although there are two FDA-approved mAb therapies for EBOV infection, these do not extend to other filoviruses. Here, we combine Fvs from broad ebolavirus mAbs to generate novel pan-ebolavirus bsAbs that are potently neutralizing, confer protection in mice, and are resistant to viral escape. Moreover, we combine Fvs from pan-ebolavirus mAbs with those of protective MARV mAbs to generate pan-filovirus protective bsAbs. These results provide guidelines for broad antiviral bsAb design and generate new immunotherapeutic candidates. Author summary: Filoviruses, such as Ebola virus and Marburg virus (EBOV and MARV, respectively), cause severe hemorrhagic fever with a high mortality rate in humans. Monoclonal antibodies (mAbs) are effective treatments for filovirus infection, but current therapies have limited breadth. Furthermore, a single mAb is susceptible to development of resistance. Here, we used protein engineering to create "bispecific" antibodies in which activities of two different mAbs were combined into one. These bispecific antibodies had broad activity, in one case providing protection against lethal challenge by two distant clades of filoviruses (EBOV and MARV). The bispecific antibodies were also less susceptible to resistance mutations. This work provides a roadmap for development of new bispecific antibody therapies for filoviruses. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Post-exposure immunotherapy for two ebolaviruses and Marburg virus in nonhuman primates
- Author
-
Brannan, Jennifer M., He, Shihua, Howell, Katie A., Prugar, Laura I., Zhu, Wenjun, Vu, Hong, Shulenin, Sergey, Kailasan, Shweta, Raina, Henna, Wong, Gary, Rahim, Md Niaz, Banadyga, Logan, Tierney, Kevin, Zhao, Xuelian, Li, Yuxing, Holtsberg, Frederick W., Dye, John M., Qiu, Xiangguo, and Aman, M. Javad
- Published
- 2019
- Full Text
- View/download PDF
4. A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses
- Author
-
Wec, Anna Z., Nyakatura, Elisabeth K., Herbert, Andrew S., Howell, Katie A., Holtsberg, Frederick W., Bakken, Russell R., Mittler, Eva, Christin, John R., Shulenin, Sergey, Jangra, Rohit K., Bharrhan, Sushma, Kuehne, Ana I., Bornholdt, Zachary A., Flyak, Andrew I., Saphire, Erica Ollmann, Crowe, James E., Aman, M. Javad, Dye, John M., Lai, Jonathan R., and Chandran, Kartik
- Published
- 2016
5. Biophysical Characterization and Conformational Stability of Ebola and Marburg Virus-Like Particles
- Author
-
Hu, Lei, Trefethen, Jared M., Zeng, Yuhong, Yee, Luisa, Ohtake, Satoshi, Lechuga‐Ballesteros, David, Warfield, Kelly L., Aman, M. Javad, Shulenin, Sergey, Unfer, Robert, Enterlein, Sven G., Truong‐Le, Vu, Volkin, David B., Joshi, Sangeeta B., and Middaugh, C. Russell
- Published
- 2011
- Full Text
- View/download PDF
6. Three ATP-binding cassette transporter genes, Abca14, Abca15, and Abca16, form a cluster on mouse Chromosome 7F3
- Author
-
Chen, Zhang-qun, Annilo, Tarmo, Shulenin, Sergey, and Dean, Michael
- Published
- 2004
- Full Text
- View/download PDF
7. Evolutionary analysis of a cluster of ATP-binding cassette (ABC) genes
- Author
-
Annilo, Tarmo, Chen, Zhang-Qun, Shulenin, Sergey, and Dean, Michael
- Published
- 2003
- Full Text
- View/download PDF
8. ABCA3 gene mutations in newborns with fatal surfactant deficiency
- Author
-
Shulenin, Sergey, Nogee, Lawrence M., Annilo, Tarmo, Wert, Susan E., Whitsett,Jeffrey A., and Dean, Michael
- Subjects
Gene mutations -- Research ,Adenosine triphosphatase genes -- Research - Abstract
The ATP-binding cassette transporter A3 (ABCA3) is extremely important for the proper formation of lamellar bodies, surfactant function and also may be required for lung function in various pulmonary diseases. Infact, the mutation of the ABCA3 gene would lead to surfactant deficiency among newborns that may turn to be fatal.
- Published
- 2004
9. Bioanalysis Young Investigator: Sathyadevi Venkataramani
- Author
-
Venkataramani, Sathyadevi and Shulenin, Sergey
- Published
- 2012
- Full Text
- View/download PDF
10. Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis
- Author
-
Tözsér, József, Shulenin, Sergey, Kádas, János, Boross, Péter, Bagossi, Péter, Copeland, Terry D, Nair, Bala C, Sarngadharan, Mangalasseril G, and Oroszlan, Stephen
- Published
- 2003
- Full Text
- View/download PDF
11. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins.
- Author
-
Quiroz, Jose A., Malonis, Ryan J., Thackray, Larissa B., Cohen, Courtney A., Pallesen, Jesper, Jangra, Rohit K., Brown, Rebecca S., Hofmann, Daniel, Holtsberg, Frederick W., Shulenin, Sergey, Nyakatura, Elisabeth K., Durnell, Lorellin A., Rayannavar, Vinayak, Daily, Johanna P., Ward, Andrew B., Aman, M. Javad, Dye, John M., Chandran, Kartik, Diamond, Michael S., and Kielian, Margaret
- Subjects
CHIKUNGUNYA virus ,ALPHAVIRUS diseases ,EPITOPES ,MEMBRANE proteins ,VIRAL mutation ,MONOCLONAL antibodies ,ANTIBODY formation ,COAT proteins (Viruses) - Abstract
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes persistent arthritis in a subset of human patients. We report the isolation and functional characterization of monoclonal antibodies (mAbs) from two patients infected with CHIKV in the Dominican Republic. Single B cell sorting yielded a panel of 46 human mAbs of diverse germline lineages that targeted epitopes within the E1 or E2 glycoproteins. MAbs that recognized either E1 or E2 proteins exhibited neutralizing activity. Viral escape mutations localized the binding epitopes for two E1 mAbs to sites within domain I or the linker between domains I and III; and for two E2 mAbs between the β-connector region and the B-domain. Two of the E2-specific mAbs conferred protection in vivo in a stringent lethal challenge mouse model of CHIKV infection, whereas the E1 mAbs did not. These results provide insight into human antibody response to CHIKV and identify candidate mAbs for therapeutic intervention. Author summary: Chikungunya virus (CHIKV) is a globally emerging virus that can cause significant disease, including a prolonged and painful arthritis. The virus is spread by mosquitoes that circulate in many regions of the world including the United States. Currently, there are no available vaccines or therapies to treat CHIKV infection. In this report, we identified and characterized a large panel of antibodies against CHIKV from two donors that contracted the viral infection in the Dominican Republic. These antibodies target a number of different regions of the membrane proteins that coat the surface of the virus, and many can inhibit the ability of CHIKV to infect cells. Two of the antibodies were shown to protect mice from a lethal dose of CHIKV. These antibodies have therapeutic potential, and provide insight into the human immune response that may facilitate vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. In Vitro processing of HIV-1 nucleocapsid protein by the viral proteinase: Effects of amino acid substitutions at the scissile bond in the proximal zinc finger sequence
- Author
-
Tozser, Jozser, Shulenin, Sergey, Copeland, Terry D., and Oroszlan, Stephen
- Subjects
Amino acids -- Analysis ,Oligopeptides -- Analysis ,Proteases -- Analysis ,HIV (Viruses) -- Research ,Biological sciences ,Chemistry - Abstract
The role of the retroviral protease in the early phase of virus replication is discussed. HIV-1 is the causative agent of acquired immunodeficiency syndrome. The kinetic parameters determined for the cleavage of oligopeptides corresponding to the cleavage sites in r-preNC correlated well with sequential processing of r-preNC.
- Published
- 2004
13. Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus.
- Author
-
Howell, Katie A., Brannan, Jennifer M., Bryan, Christopher, McNeal, Andrew, Davidson, Edgar, Turner, Hannah L., Vu, Hong, Shulenin, Sergey, He, Shihua, Kuehne, Ana, Herbert, Andrew S., Qiu, Xiangguo, Doranz, Benjamin J., Holtsberg, Frederick W., Ward, Andrew B., Dye, John M., and Aman, M. Javad
- Abstract
Summary Drug combinations are synergistic when their combined efficacy exceeds the sum of the individual actions, but they rarely include ineffective drugs that become effective only in combination. We identified several “enabling pairs” of neutralizing and non-neutralizing anti-ebolavirus monoclonal antibodies, whose combination exhibited new functional profiles, including transforming a non-neutralizing antibody to a neutralizer. Sub-neutralizing concentrations of antibodies 2G4 or m8C4 enabled non-neutralizing antibody FVM09 (IC 50 >1 μM) to exhibit potent neutralization (IC 50 1–10 nM). While FVM09 or m8C4 alone failed to protect Ebola-virus-infected mice, a combination of the two antibodies provided 100% protection. Furthermore, non-neutralizers FVM09 and FVM02 exponentially enhanced the potency of two neutralizing antibodies against both Ebola and Sudan viruses. We identified a hotspot for the binding of these enabling antibody pairs near the interface of the glycan cap and GP2. Enabling cooperativity may be an underappreciated phenomenon for viruses, with implications for the design and development of immunotherapeutics and vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site.
- Author
-
Howell, Katie A., Qiu, Xiangguo, Brannan, Jennifer M., Bryan, Christopher, Davidson, Edgar, Holtsberg, Frederick W., Wec, Anna Z., Shulenin, Sergey, Biggins, Julia E., Douglas, Robin, Enterlein, Sven G., Turner, Hannah L., Pallesen, Jesper, Murin, Charles D., He, Shihua, Kroeker, Andrea, Vu, Hong, Herbert, Andrew S., Fusco, Marnie L., and Nyakatura, Elisabeth K.
- Abstract
Summary Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a monoclonal antibody (FVM04) that targets a uniquely exposed epitope within the RBS; cross-neutralizes Ebola (EBOV), Sudan (SUDV), and, to a lesser extent, Bundibugyo viruses; and shows protection against EBOV and SUDV in mice and guinea pigs. The antibody cocktail ZMapp™ is remarkably effective against EBOV (Zaire) but does not cross-neutralize other ebolaviruses. By replacing one of the ZMapp™ components with FVM04, we retained the anti-EBOV efficacy while extending the breadth of protection to SUDV, thereby generating a cross-protective antibody cocktail. In addition, we report several mutations at the base of the ebolavirus glycoprotein that enhance the binding of FVM04 and other cross-reactive antibodies. These findings have important implications for pan-ebolavirus vaccine development and defining broadly protective antibody cocktails. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
15. Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans.
- Author
-
Vu, Hong, Shulenin, Sergey, Grolla, Allen, Audet, Jonathan, He, Shihua, Kobinger, Gary, Unfer, Robert C., Warfield, Kelly L., Aman, M. Javad, and Holtsberg, Frederick W.
- Subjects
- *
SEROLOGY , *VIRAL antibodies , *EBOLA virus , *VIRAL proteins , *EXTRACELLULAR matrix proteins - Abstract
The West Africa Ebola virus disease (EVD) outbreak has reached unprecedented magnitude and caused worldwide concerns for the spread of this deadly virus. Recent findings in nonhuman primates (NHPs) demonstrate that antibodies can be protective against EVD. However, the role of antibody response in vaccine-mediated protection is not fully understood. To address these questions quantitative serology assays are needed for measurement of the antibody response to key Ebola virus (EBOV) proteins. Serology enzyme-linked immunosorbent assays (ELISA's), using a reference detection antibody, were developed in order to standardize the quantitation of antibody levels in vaccinated NHPs or in humans exposed to EBOV or immunized with an EBOV vaccine. Critical reagents were generated to support the development of the serology ELISAs. Recombinant EBOV matrix protein (VP40) was expressed in Escherichia coli and purified. Two variants of the glycoprotein (GP), the ectodomain lacking the transmembrane domain (GPΔTM), and an engineered GP lacking the mucin-like domain (GPΔmuc) were expressed and purified from mammalian cell systems. Using these proteins, three ELISA methods were developed and optimized for reproducibility and robustness, including stability testing of critical reagents. The assay was used to determine the antibody response against VP40, GPΔTM, and GPΔmuc in a NHP vaccine study using EBOV virus-like particles (VLP) vaccine expressing GP, VP40 and the nucleoprotein. Additionally, these ELISAs were used to successfully detect antibody responses to VP40, GPΔTM and GPΔmuc in human sera from EBOV infected individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Pan-ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection against Ebola and Sudan Viruses.
- Author
-
Holtsberg, Frederick W., Shulenin, Sergey, Hong Vu, Howell, Katie A., Patel, Sonal J., Gunn, Bronwyn, Karim, Marcus, Lai, Jonathan R., Frei, Julia C., Nyakatur, Elisabeth K., Zeitlin, Larry, Douglas, Robin, Fusco, Marnie L., Froude, Jeffrey W., Saphire, Erica Ollmann, Herbert, Andrew S., Wirchnianski, Ariel S., Lear-Rooney, Calli M., Alter, Galit, and Dye, John M.
- Subjects
- *
EBOLA virus disease , *EPIDEMICS , *FILOVIRIDAE , *MONOCLONAL antibodies , *GLYCOPROTEINS - Abstract
The unprecedented 2014-2015 Ebola virus disease (EVD) outbreak in West Africa has highlighted the need for effective therapeutics against filoviruses. Monoclonal antibody (MAb) cocktails have shown great potential as EVD therapeutics; however, the existing protective MAbs are virus species specific. Here we report the development of pan-ebolavirus and pan-filovirus antibodies generated by repeated immunization of mice with filovirus glycoproteins engineered to drive the B cell responses toward conserved epitopes. Multiple pan-ebolavirus antibodies were identified that react to the Ebola, Sudan, Bundibugyo, and Reston viruses. A pan-filovirus antibody that was reactive to the receptor binding regions of all filovirus glycoproteins was also identified. Significant postexposure efficacy of several MAbs, including a novel antibody cocktail, was demonstrated. For the first time, we report cross-neutralization and in vivo protection against two highly divergent filovirus species, i.e., Ebola virus and Sudan virus, with a single antibody. Competition studies indicate that this antibody targets a previously unrecognized conserved neutralizing epitope that involves the glycan cap. Mechanistic studies indicated that, besides neutralization, innate immune cell effector functions may play a role in the antiviral activity of the antibodies. Our findings further suggest critical novel epitopes that can be utilized to design effective cocktails for broad protection against multiple filovirus species. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs.
- Author
-
Adhikari, Rajan P., Kort, Thomas, Shulenin, Sergey, Kanipakala, Tulasikumari, Ganjbaksh, Nader, Roghmann, Mary-Claire, Holtsberg, Frederick W., and Aman, M. Javad
- Subjects
IMMUNOGLOBULINS ,LEUKOTOXINS ,STAPHYLOCOCCUS aureus ,HEMOLYSIS & hemolysins ,IMMUNOSUPPRESSION - Abstract
S. aureus vaccine development has proven particularly difficult. The conventional approach to achieve sterile immunity through opsonophagocytic killing has been largely unsuccessful. S. aureus is highly toxigenic and a great body of evidence suggests that a successful future vaccine for this organism should target extracellular toxins which are responsible for host tissue destruction and immunosuppression. Major staphylococcal toxins are alpha toxin (a single subunit hemolysin) along with a group of bicomponent pore-forming toxins (BCPFT), namely Panton-Valentine leukocidin (PVL), gamma hemolysins (HlgCB and AB), LukAB and LukED. In our previous report, an attenuated mutant of LukS-PV (PVL- S subunit) named as “LukS-mut9” elicited high immunogenic response as well as provided a significant protection in a mouse sepsis model. Recent discovery of PVL receptors shows that mice lack receptors for this toxin, thus the reported protection of mice with the PVL vaccine may relate to cross protective responses against other homologous toxins. This manuscript addresses this issue by demonstrating that polyclonal antibody generated by LukS-mut9 can neutralize other canonical and non-canonical leukotoxin pairs. In this report, we also demonstrated that several potent toxins can be created by non-canonical pairing of subunits. Out of 5 pairs of canonical and 8 pairs of non-canonical toxins tested, anti-LukS-mut9 polyclonal antibodies neutralized all except for LukAB. We also studied the potential hemolytic activities of canonical and noncanonical pairs among biocomponent toxins and discovered that a novel non-canonical pair consisting of HlgA and LukD is a highly toxic combination. This pair can lyse RBC from different species including human blood far better than alpha hemolysin. Moreover, to follow-up our last report, we explored the correlation between the levels of pre-existing antibodies to new sets of leukotoxins subunits and clinical outcomes in adult patients with S. aureus bacteremia. We found that there is an inversed correlation between the antibody titer to sepsis for leukotoxins LukS-mut9, LukF-PV, HlgC, LukE and LukAB, suggesting the risk of sepsis was significantly lower in the patients with higher antibody titer against those toxins. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
18. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs.
- Author
-
Fusco, Marnie L., Hashiguchi, Takao, Cassan, Robyn, Biggins, Julia E., Murin, Charles D., Warfield, Kelly L., Li, Sheng, Holtsberg, Frederick W., Shulenin, Sergey, Vu, Hong, Olinger, Gene G., Kim, Do H., Whaley, Kevin J., Zeitlin, Larry, Ward, Andrew B., Nykiforuk, Cory, Aman, M. Javad, Berry, Jody, and Saphire, Erica Ollmann
- Subjects
FILOVIRIDAE ,MARBURG virus disease ,EBOLA virus ,IMMUNOGLOBULINS ,GLYCOPROTEINS - Abstract
The filoviruses, which include the marburg- and ebolaviruses, have caused multiple outbreaks among humans this decade. Antibodies against the filovirus surface glycoprotein (GP) have been shown to provide life-saving therapy in nonhuman primates, but such antibodies are generally virus-specific. Many monoclonal antibodies (mAbs) have been described against Ebola virus. In contrast, relatively few have been described against Marburg virus. Here we present ten mAbs elicited by immunization of mice using recombinant mucin-deleted GPs from different Marburg virus (MARV) strains. Surprisingly, two of the mAbs raised against MARV GP also cross-react with the mucin-deleted GP cores of all tested ebolaviruses (Ebola, Sudan, Bundibugyo, Reston), but these epitopes are masked differently by the mucin-like domains themselves. The most efficacious mAbs in this panel were found to recognize a novel “wing” feature on the GP2 subunit that is unique to Marburg and does not exist in Ebola. Two of these anti-wing antibodies confer 90 and 100% protection, respectively, one hour post-exposure in mice challenged with MARV. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles.
- Author
-
Warfield, Kelly L., Dye, John M., Wells, Jay B., Unfer, Robert C., Holtsberg, Frederick W., Shulenin, Sergey, Vu, Hong, Swenson, Dana L., Bavari, Sina, and Aman, M. Javad
- Subjects
EBOLA virus ,VIRUS-like particles ,FILOVIRIDAE ,HEMORRHAGIC fever ,KRA ,HOMOLOGY (Biology) ,MORTALITY - Abstract
Filoviruses cause hemorrhagic fever resulting in significant morbidity and mortality in humans. Several vaccine platforms that include multiple virus-vectored approaches and virus-like particles (VLPs) have shown efficacy in nonhuman primates. Previous studies have shown protection of cynomolgus macaques against homologous infection for Ebola virus (EBOV) and Marburg virus (MARV) following a three-dose vaccine regimen of EBOV or MARV VLPs, as well as heterologous protection against Ravn Virus (RAVV) following vaccination with MARV VLPs. The objectives of the current studies were to determine the minimum number of vaccine doses required for protection (using EBOV as the test system) and then demonstrate protection against Sudan virus (SUDV) and Taï Forest virus (TAFV). Using the EBOV nonhuman primate model, we show that one or two doses of VLP vaccine can confer protection from lethal infection. VLPs containing the SUDV glycoprotein, nucleoprotein and VP40 matrix protein provide complete protection against lethal SUDV infection in macaques. Finally, we demonstrate protective efficacy mediated by EBOV, but not SUDV, VLPs against TAFV; this is the first demonstration of complete cross-filovirus protection using a single component heterologous vaccine within the Ebolavirus genus. Along with our previous results, this observation provides strong evidence that it will be possible to develop and administer a broad-spectrum VLP-based vaccine that will protect against multiple filoviruses by combining only three EBOV, SUDV and MARV components. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
20. Structurally Designed Attenuated Subunit Vaccines for S. aureus LukS-PV and LukF-PV Confer Protection in a Mouse Bacteremia Model.
- Author
-
Karauzum, Hatice, Adhikari, Rajan P., Sarwar, Jawad, Devi, V. Sathya, Abaandou, Laura, Haudenschild, Christian, Mahmoudieh, Mahta, Boroun, Atefeh R., Vu, Hong, Nguyen, Tam, Warfield, Kelly L., Shulenin, Sergey, and Aman, M. Javad
- Subjects
DRUG design ,VACCINES ,STAPHYLOCOCCUS aureus infections ,CELL surface antigens ,DRUG development ,MICROBIAL virulence ,IMMUNOSUPPRESSIVE agents ,IMMUNOLOGY ,THERAPEUTICS - Abstract
Previous efforts towards S. aureus vaccine development have largely focused on cell surface antigens to induce opsonophagocytic killing aimed at providing sterile immunity, a concept successfully applied to other Gram-positive pathogens such as Streptococcus pneumoniae. However, these approaches have largely failed, possibly in part due to the remarkable diversity of the staphylococcal virulence factors such as secreted immunosuppressive and tissue destructive toxins. S. aureus produces several pore-forming toxins including the single subunit alpha hemolysin as well as bicomponent leukotoxins such as Panton-Valentine leukocidin (PVL), gamma hemolysins (Hlg), and LukED. Here we report the generation of highly attenuated mutants of PVL subunits LukS-PV and LukF-PV that were rationally designed, based on an octameric structural model of the toxin, to be deficient in oligomerization. The attenuated subunit vaccines were highly immunogenic and showed significant protection in a mouse model of S. aureus USA300 sepsis. Protection against sepsis was also demonstrated by passive transfer of rabbit immunoglobulin raised against LukS-PV. Antibodies to LukS-PV inhibited the homologous oligomerization of LukS-PV with LukF-PV as well heterologous oligomerization with HlgB. Importantly, immune sera from mice vaccinated with the LukS mutant not only inhibited the PMN lytic activity produced by the PVL-positive USA300 but also blocked PMN lysis induced by supernatants of PVL-negative strains suggesting a broad protective activity towards other bicomponent toxins. These findings strongly support the novel concept of an anti-virulence, toxin-based vaccine intended for prevention of clinical S. aureus invasive disease, rather than achieving sterile immunity. Such a multivalent vaccine may include attenuated leukotoxins, alpha hemolysin, and superantigens. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Novel Structurally Designed Vaccine for S. aureus α-Hemolysin: Protection against Bacteremia and Pneumonia.
- Author
-
Adhikari, Rajan P., Karauzum, Hatice, Sarwar, Jawad, Abaandou, Laura, Mahmoudieh, Mahta, Boroun, Atefeh R., Hong Vu, Nguyen, Tam, Devi, V. Sathya, Shulenin, Sergey, Warfield, Kelly L., and Aman, M. Javad
- Subjects
STAPHYLOCOCCUS aureus ,SEPSIS ,PNEUMONIA ,HEMOLYSIS & hemolysins ,GLUCOPYRANOSE - Abstract
Staphylococcus aureus (S. aureus) is a human pathogen associated with skin and soft tissue infections (SSTI) and life threatening sepsis and pneumonia. Efforts to develop effective vaccines against S. aureus have been largely unsuccessful, in part due to the variety of virulence factors produced by this organism. S. aureus alpha-hemolysin (Hla) is a pore-forming toxin expressed by most S. aureus strains and reported to play a key role in the pathogenesis of SSTI and pneumonia. Here we report a novel recombinant subunit vaccine candidate for Hla, rationally designed based on the heptameric crystal structure. This vaccine candidate, denoted AT-62aa, was tested in pneumonia and bacteremia infection models using S. aureus strain Newman and the pandemic strain USA300 (LAC). Significant protection from lethal bacteremia/sepsis and pneumonia was observed upon vaccination with AT-62aa along with a Glucopyranosyl Lipid Adjuvant-Stable Emulsion (GLA-SE) that is currently in clinical trials. Passive transfer of rabbit immunoglobulin against AT-62aa (AT62-IgG) protected mice against intraperitoneal and intranasal challenge with USA300 and produced significant reduction in bacterial burden in blood, spleen, kidney, and lungs. Our Hla-based vaccine is the first to be reported to reduce bacterial dissemination and to provide protection in a sepsis model of S. aureus infection. AT62-IgG and sera from vaccinated mice effectively neutralized the toxin in vitro and AT62-IgG inhibited the formation of Hla heptamers, suggesting antibody-mediated neutralization as the primary mechanism of action. This remarkable efficacy makes this Hla-based vaccine a prime candidate for inclusion in future multivalent S. aureus vaccine. Furthermore, identification of protective epitopes within AT-62aa could lead to novel immunotherapy for S. aureus infection. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. Characterization of human immunodeficiency virus type 1 (HIV-1) containing mutations in the nucleocapsid protein at a putative HIV-1 protease cleavage site
- Author
-
Thomas, James A., Shulenin, Sergey, Coren, Lori V., Bosche, William J., Gagliardi, Tracy D., Gorelick, Robert J., and Oroszlan, Stephen
- Subjects
- *
HIV , *HIV infections , *NUCLEIC acids , *CELL culture - Abstract
Abstract: The HIV-1 nucleocapsid protein (NC) has been hypothesized to be cleaved by the viral protease (PR) during early infection. Characterization of viruses, with amino-acid substitutions that modulate PR cleavage of NC in vitro, was performed in cell culture. Two of the NC mutants, NCN17F and NCN17G, had decreased infectivity and exhibited severe H9 replication defects. Examination of viral DNA after infections revealed defects in reverse transcription and integration, although integration defects were cell-type dependent. However, while the defects in reverse transcription and integration correlate with lowered infectivity in a single-round of infection, they did not approach the magnitude of the replication defect measured in H9 cells over multiple rounds. Importantly, we fail to see evidence that H9 cells are re-infected with the NCN17G and NCN17F viruses 24 h after the initial infection, which suggests that the principal defect caused by these NC mutations occurs during late events of viral replication. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
23. SMUCKLER/TIM4 is a distinct member of TIM family expressed by stromal cells of secondary lymphoid tissues and associated with lymphotoxin signaling.
- Author
-
Shakhov, Alexander N., Rybtsov, Stanislav, Tumanov, Alexei V., Shulenin, Sergey, Dean, Michael, Kuprash, Dmitry V., and Nedospasov, Sergei A.
- Abstract
Lymphotoxin-α (LTα) was originally linked to delayed-type hypersensitivity and its production was later attributed to Th1, but not Th2 cells. Studies employing knockout mice demonstrated that LT signaling is essential for the development and functional compartmentalization of lymphoid tissues. Here, using gene expression profiling, we identified a novel gene termed SMUCKLER (spleen, mucin-containing, knockout of lymphotoxin), that is selectively down-regulated in spleens of LTα- or LTβ-deficient mice. The encoded transmembrane protein contains immunoglobulin V and mucin domains and is identical to TIM4, a predicted member of recently identified TIM family (T cell immunoglobulin- and mucin-domain-containing molecule). Unlike TIM1 and TIM3, which were implicatedin T cell-mediated functions, SMUCKLER lacks tyrosine phosphorylation motif in its intracellular domain and is not expressed by bone marrow-derived cells. In situ hybridization of spleen sections demonstrated SMUCKLER expression by stromal cells predominantly in the marginal zone and to a lesser extent throughout the white pulp. Similarly to other TIM genes, SMUCKLER maps to a locus associated with predisposition to asthma both in mice and in humans (11.b1 and 5q33, respectively) and shows coding sequence variations between BALB/c and DBA mice. Therefore, SMUCKLER/TIM4 may be considered as a candidate disease-predisposition gene for asthma. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
24. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption.
- Author
-
Lee, Mi-Hye, Lu, Kangmo, Hazard, Star, Yu, Hongwei, Shulenin, Sergey, Hidaka, Hideki, Kojima, Hideto, Allikmets, Rando, Sakuma, Nagahiko, Pegoraro, Rosemary, Srivastava, Anand K., Salen, Gerald, Dean, Michael, and Patel, Shailendra B.
- Subjects
CHOLESTEROL ,DIET ,MEDICAL genetics - Abstract
The molecular mechanisms regulating the amount of dietary cholesterol retained in the body, as well as the body's ability to exclude selectively other dietary sterols, are poorly understood. An average western diet will contain about 250?500 mg of dietary cholesterol and about 200?400 mg of non-cholesterol sterols. About 50?60% of the dietary cholesterol is absorbed and retained by the normal human body, but less than 1% of the non-cholesterol sterols are retained. Thus, there exists a subtle mechanism that allows the body to distinguish between cholesterol and non-cholesterol sterols. In sitosterolemia, a rare autosomal recessive disorder, affected individuals hyperabsorb not only cholesterol but also all other sterols, including plant and shellfish sterols from the intestine. The major plant sterol species is sitosterol; hence the name of the disorder. Consequently, patients with this disease have very high levels of plant sterols in the plasma and develop tendon and tuberous xanthomas, accelerated atherosclerosis, and premature coronary artery disease. We previously mapped the STSL locus to human chromosome 2p21 (ref. 4) and further localized it to a region of less than 2 cM bounded by markers D2S2294 and D2S2291 (M.-H.L. et al., manuscript submitted). We now report that a new member of the ABC transporter family, ABCG5, is mutant in nine unrelated sitosterolemia patients. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
25. Correction: Antibodies to S. aureus LukS-PV Attenuated Subunit Vaccine Neutralize a Broad Spectrum of Canonical and Non-Canonical Bicomponent Leukotoxin Pairs.
- Author
-
Adhikari, Rajan P., Kort, Thomas, Shulenin, Sergey, Kanipakala, Tulasikumari, Ganjbaksh, Nader, Roghmann, Mary-Claire, Holtsberg, Frederick W., and Aman, M. Javad
- Subjects
PUBLISHED errata ,PUBLISHING ,PERIODICAL articles ,PERIODICAL publishing ,PUBLISHED articles - Published
- 2015
- Full Text
- View/download PDF
26. Evolution of the vertebrate ABC gene family: Analysis of gene birth and death
- Author
-
Annilo, Tarmo, Chen, Zhang-Qun, Shulenin, Sergey, Costantino, Julie, Thomas, Lauren, Lou, Hong, Stefanov, Stefan, and Dean, Michael
- Subjects
- *
VERTEBRATES , *ATP-binding cassette transporters , *BILAYER lipid membranes , *CHROMOSOMAL translocation - Abstract
Abstract: Vertebrate evolution has been largely driven by the duplication of genes that allow for the acquisition of new functions. The ATP-binding cassette (ABC) proteins constitute a large and functionally diverse family of membrane transporters. The members of this multigene family are found in all cellular organisms, most often engaged in the translocation of a wide variety of substrates across lipid membranes. Because of the diverse function of these genes, their large size, and the large number of orthologs, ABC genes represent an excellent tool to study gene family evolution. We have identified ABC proteins from the sea squirt (Ciona intestinalis), zebrafish (Danio rerio), and chicken (Gallus gallus) and, using phylogenetic analysis, identified those genes with a one-to-one orthologous relationship to human ABC proteins. All ABC protein subfamilies found in Ciona and zebrafish correspond to the human subfamilies, with the exception of a single ABCH subfamily gene found only in zebrafish. Multiple gene duplication and deletion events were identified in different lineages, indicating an ongoing process of gene evolution. As many ABC genes are involved in human genetic diseases, and important drug transport phenotypes, the understanding of ABC gene evolution is important to the development of animal models and functional studies. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
27. Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.
- Author
-
Nyakatura, Elisabeth K., Zak, Samantha E., Wec, Anna Z., Hofmann, Daniel, Shulenin, Sergey, Bakken, Russell R., Aman, M. Javad, Chandran, Kartik, Dye, John M., and Lai, Jonathan R.
- Subjects
- *
FILOVIRIDAE , *GLYCOPROTEINS , *THERAPEUTIC use of immunoglobulins , *IMMUNOLOGY , *VIRUS diseases , *EBOLA virus , *THERAPEUTICS - Abstract
Filoviruses (family Filoviridae) include five ebolaviruses and Marburg virus. These pathogens cause a rapidly progressing and severe viral disease with high mortality rates (generally 30-90%). Outbreaks of filovirus disease are sporadic and, until recently, were limited to less than 500 cases. However, the 2013-2016 epidemic in western Africa, caused by Ebola virus (EBOV), illustrated the potential of filovirus outbreaks to escalate to a much larger scale (over 28,000 suspected cases). mAbs against the envelope glycoprotein represent a promising therapeutic platform for managing filovirus infections. However, mAbs that exhibit neutralization or protective properties against multiple filoviruses are rare. Here we examined a panel of engineered biand trispecific antibodies, in which variable domains of mAbs that target epitopes from multiple filoviruses were combined, for their capacity to neutralize viral infection across filovirus species. We found that bispecific combinations targeting EBOV and Sudan virus (another ebolavirus), provide potent cross-neutralization and protection in mice. Furthermore, trispecific combinations, targeting EBOV, Sudan virus, and Marburg virus, exhibited strong neutralization potential against all three viruses. These results provide important insights into multispecific antibody engineering against filoviruses and will inform future immunotherapeutic discoveries. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
28. A“Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses.
- Author
-
Wec, Anna Z., Nyakatura, Elisabeth K., Herbert, Andrew S., Howell, Katie A., Holtsberg, Frederick W., Bakken, Russell R., Mittler, Eva, Christin, John R., Shulenin, Sergey, Jangra, Rohit K., Bharrhan, Sushma, Kuehne, Ana I., Bornholdt, Zachary A., Flyak, Andrew I., Saphire, Erica Ollmann, Crowe Jr., James E., Aman, M. Javad, Dye, John M., Lai, Jonathan R., and Chandran, Kartik
- Subjects
- *
BISPECIFIC antibodies , *EBOLA virus , *GLYCOPROTEINS , *EPITOPES , *IMMUNOTHERAPY - Abstract
There is an urgent need for monoclonal antibody (mAb) therapies that broadly protect against Ebola virus and other filoviruses. The conserved, essential interaction between the filovirus glycoprotein, GP, and its entry receptor Niemann-Pick C1 (NPC1) provides an attractive target for such mAbs but is shielded by multiple mechanisms, including physical sequestration in late endosomes. Here, we describe a bispecific-antibody strategy to target this interaction, in which mAbs specific for NPC1 or the GP receptor–binding site are coupled to a mAb against a conserved, surface-exposed GP epitope. Bispecific antibodies, but not parent mAbs, neutralized all known ebolaviruses by coopting viral particles themselves for endosomal delivery and conferred postexposure protection against multiple ebolaviruses in mice. Such “Trojan horse” bispecific antibodies have potential as broad antifilovirus immunotherapeutics. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
29. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
- Author
-
Zhen-Yong Keck, Enterlein, Sven G., Howell, Katie A., Vu, Hong, Shulenin, Sergey, Warfield, Kelly L., Froude, Jeffrey W., Araghi, Nazli, Douglas, Robin, Biggins, Julia, Lear-Rooney, Calli M., Wirchnianski, Ariel S., Lau, Patrick, Yong Wang, Herbert, Andrew S., Dye, John M., Glass, Pamela J., Holtsberg, Frederick W., Foung, Steven K. H., and Aman, M. Javad
- Subjects
- *
FILOVIRIDAE , *IMMUNOTHERAPY , *MONOCLONAL antibodies , *IMMUNOGLOBULINS - Abstract
Filoviruses cause highly lethal viral hemorrhagic fever in humans and nonhuman primates. Current immunotherapeutic options for filoviruses are mostly specific to Ebola virus (EBOV), although other members of Filoviridae such as Sudan virus (SUDV), Bundibugyo virus (BDBV), and Marburg virus (MARV) have also caused sizeable human outbreaks. Here we report a set of pan-ebolavirus and pan-filovirus monoclonal antibodies (MAbs) derived from cynomolgus macaques immunized repeatedly with a mixture of engineered glycoproteins (GPs) and virus-like particles (VLPs) for three different filovirus species. The antibodies recognize novel neutralizing and nonneutralizing epitopes on the filovirus glycoprotein, including conserved conformational epitopes within the core regions of the GP1 subunit and a novel linear epitope within the glycan cap. We further report the first filovirus antibody binding to a highly conserved epitope within the fusion loop of ebolavirus and marburgvirus species. One of the antibodies binding to the core GP1 region of all ebolavirus species and with lower affinity to MARV GP cross neutralized both SUDV and EBOV, the most divergent ebolavirus species. In a mouse model of EBOV infection, this antibody provided 100% protection when administered in two doses and partial, but significant, protection when given once at the peak of viremia 3 days postinfection. Furthermore, we describe novel cocktails of antibodies with enhanced protective efficacy compared to individual MAbs. In summary, the present work describes multiple novel, cross-reactive filovirus epitopes and innovative combination concepts that challenge the current therapeutic models. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
30. Synthetic Human Monoclonal Antibodies toward Staphylococcal Enterotoxin B (SEB) Protective against Toxic Shock Syndrome.
- Author
-
Karauzum, Hatice, Gang Chen, Abaandou, Laura, Mahmoudieh, Mahta, Boroun, Atefeh R., Shulenin, Sergey, Devi, V. Sathya, Stavale, Eric, Warfield, Kelly L., Zeitlin, Larry, Roy, Chad J., Sidhu, Sachdev S., and Aman, M. Javad
- Subjects
- *
MONOCLONAL antibodies , *ENTEROTOXINS , *STAPHYLOCOCCUS , *TOXIC shock syndrome , *IMMUNOGLOBULIN G , *BIOCHEMISTRY , *SYNTHETIC antibodies - Abstract
Staphylococcal enterotoxin B (SEB) is a potent toxin that can cause toxic shock syndrome and act as a lethal and incapacitating agent when used as a bioweapon. There are currently no vaccines or immunotherapeutics available against this toxin. Using phage display technology, human antigen-binding fragments (Fabs) were selected against SEB, and proteins were produced in Escherichia coli cells and characterized for their binding affinity and their toxin neutralizing activity in vitro and in vivo. Highly protective Fabs were converted into full-length IgGs and produced in mammalian cells. Additionally, the production of anti-SEB antibodies was explored in the Nicotiana benthamiana plant expression system. Affinity maturation was performed to produce optimized lead anti-SEB antibody candidates with subnanomolar affinities. IgGs produced in N. benthamiana showed characteristics comparable with those of counterparts produced in mammalian cells. IgGs were tested for their therapeutic efficacy in the mouse toxic shock model using different challenge doses of SEB and a treatment with 200 μg of IgGs 1 h after SEB challenge. The lead candidates displayed full protection from lethal challenge over a wide range of SEB challenge doses. Furthermore, mice that were treated with anti-SEB IgG had significantly lower IFNγ and IL-2 levels in serum compared with mock-treated mice. In summary, these anti-SEB monoclonal antibodies represent excellent therapeutic candidates for further preclinical and clinical development. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
31. Effects of human TRIM5α polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection
- Author
-
Javanbakht, Hassan, An, Ping, Gold, Bert, Petersen, Desiree C., O'Huigin, Colm, Nelson, George W., O'Brien, Stephen J., Kirk, Gregory D., Detels, Roger, Buchbinder, Susan, Donfield, Sharyne, Shulenin, Sergey, Song, Byeongwoon, Perron, Michel J., Stremlau, Matthew, Sodroski, Joseph, Dean, Michael, and Winkler, Cheryl
- Subjects
- *
HIV infections , *HIV , *GENETIC polymorphisms , *VIRUS diseases , *TISSUE culture - Abstract
Abstract: TRIM5α acts on several retroviruses, including human immunodeficiency virus (HIV-1), to restrict cross-species transmission. Using natural history cohorts and tissue culture systems, we examined the effect of polymorphism in human TRIM5α on HIV-1 infection. In African Americans, the frequencies of two non-coding SNP variant alleles in exon 1 and intron 1 of TRIM5 were elevated in HIV-1-infected persons compared with uninfected subjects. By contrast, the frequency of the variant allele encoding TRIM5α 136Q was relatively elevated in uninfected individuals, suggesting a possible protective effect. TRIM5α 136Q protein exhibited slightly better anti-HIV-1 activity in tissue culture than the TRIM5α R136 protein. The 43Y variant of TRIM5α was less efficient than the H43 variant at restricting HIV-1 and murine leukemia virus infections in cultured cells. The ancestral TRIM5 haplotype specifying no observed variant alleles appeared to be protective against infection, and the corresponding wild-type protein partially restricted HIV-1 replication in vitro. A single logistic regression model with a permutation test indicated the global corrected P value of <0.05 for both SNPs and haplotypes. Thus, polymorphism in human TRIM5 may influence susceptibility to HIV-1 infection, a possibility that merits additional evaluation in independent cohorts. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
32. Comparative genome analysis of potential regulatory elements in the ABCG5–ABCG8 gene cluster
- Author
-
Remaley, Alan T., Bark, Samantha, Walts, Avram D., Freeman, Lita, Shulenin, Sergey, Annilo, Tarmo, Elgin, Eric, Rhodes, Hope E., Joyce, Charles, Dean, Michael, Santamarina-Fojo, Silvia, and Brewer Jr., H. Bryan
- Subjects
- *
STEROLS , *GENOMES , *GENES - Abstract
The excretion of sterols from the liver and intestine is regulated by the ABCG5 and ABCG8 transporters. To identify potential regulatory elements, 152 kb of the human ABCG5–ABCG8 gene cluster was sequenced and comparative genome analysis was performed. The two genes are oriented in a head-to-head configuration and are separated by a 374-bp intergenic region, which is highly conserved among several species. Using a reporter construct, the intergenic region was found to act as a bidirectional promoter. A conserved GATA site in the intergenic region was shown by site-directed mutagenesis to act as a repressor for the ABCG5 promoter. The intergenic region was also shown to be partially responsive to treatment by LXR agonists. In summary, several potential regulatory elements were found for the ABCG5 and ABCG8 genes, and the intergenic region was found to act as a bidirectional promoter. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
33. Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.
- Author
-
Zhao, Xuelian, Howell, Katie A., He, Shihua, Brannan, Jennifer M., Wec, Anna Z., Davidson, Edgar, Turner, Hannah L., Chiang, Chi-I., Lei, Lin, Fels, J. Maximilian, Vu, Hong, Shulenin, Sergey, Turonis, Ashley N., Kuehne, Ana I., Liu, Guodong, Ta, Mi, Wang, Yimeng, Sundling, Christopher, Xiao, Yongli, and Spence, Jennifer S.
- Subjects
- *
EBOLA virus disease vaccines , *CHIMERIC proteins , *VIRAL antibodies , *GLYCOPROTEINS , *VIRAL proteins - Abstract
Summary While neutralizing antibodies are highly effective against ebolavirus infections, current experimental ebolavirus vaccines primarily elicit species-specific antibody responses. Here, we describe an immunization-elicited macaque antibody (CA45) that clamps the internal fusion loop with the N terminus of the ebolavirus glycoproteins (GPs) and potently neutralizes Ebola, Sudan, Bundibugyo, and Reston viruses. CA45, alone or in combination with an antibody that blocks receptor binding, provided full protection against all pathogenic ebolaviruses in mice, guinea pigs, and ferrets. Analysis of memory B cells from the immunized macaque suggests that elicitation of broadly neutralizing antibodies (bNAbs) for ebolaviruses is possible but difficult, potentially due to the rarity of bNAb clones and their precursors. Unexpectedly, germline-reverted CA45, while exhibiting negligible binding to full-length GP, bound a proteolytically remodeled GP with picomolar affinity, suggesting that engineered ebolavirus vaccines could trigger rare bNAb precursors more robustly. These findings have important implications for developing pan-ebolavirus vaccine and immunotherapeutic cocktails. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.